Back to Search
Start Over
Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis.
- Source :
-
Clinical endocrinology [Clin Endocrinol (Oxf)] 2013 Oct; Vol. 79 (4), pp. 499-503. Date of Electronic Publication: 2013 Apr 01. - Publication Year :
- 2013
-
Abstract
- Objective: Denosumab is a new potent antiresorptive treatment of osteoporosis that can potentially induce a compensatory increase in parathyroid hormone (PTH) levels. We aimed to evaluate the alteration of PTH 1 and 6 months after denosumab's administration with different regimens of calcium and vitamin D (Ca/D) supplementation.<br />Design: Prospective, multicenter, study in a relatively small, heterogeneous sample of postmenopausal women followed for 6 months.<br />Patients: Forty seven postmenopausal women followed in 2 outpatient clinics, requiring onset or continuation of osteoporosis treatment. We administered 1 g calcium carbonate and 800 IU cholecalciferol daily for 6 months (Group A) or the double dose for the first month followed by the 1 g/800 IU Ca/D regimen for the next 5 months (Group B).<br />Measurements: Parathyroid hormone (PTH) alterations between and within groups, and their associations with serum Ca and bone markers.<br />Results: Parathyroid hormone (PTH) levels were significantly higher at month 1 and 6 only in Group A; Ca levels were significantly decreased at month 1 and returned to baseline values at month 6 within the same Group. The mean per cent change between month 1 and baseline for PTH [Δ(PTH1-0 )] was significantly higher in Group A than B (63·5% ± 28·2% vs -3·0% ± 4·7%, P = 0·029). Δ(PTH1-0 ) was correlated with the reciprocal Δ-changes of Ca (rs  = -0·610; P = 0·002) and collagen type I C-terminal telopeptide (rs  = -0·697; P = 0·003) only in Group A.<br />Conclusions: An increase in PTH should be expected, at least following the first administration of denosumab in common clinical practice. The effect of this compensatory onsequence in bone metabolism warrants further investigation.<br /> (© 2013 John Wiley & Sons Ltd.)
- Subjects :
- Aged
Bone Density drug effects
Calcium blood
Calcium Carbonate therapeutic use
Cholecalciferol therapeutic use
Denosumab
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Therapy, Combination
Female
Humans
Middle Aged
Prospective Studies
Time Factors
Treatment Outcome
Vitamins therapeutic use
Antibodies, Monoclonal, Humanized therapeutic use
Osteoporosis, Postmenopausal blood
Osteoporosis, Postmenopausal drug therapy
Parathyroid Hormone blood
Subjects
Details
- Language :
- English
- ISSN :
- 1365-2265
- Volume :
- 79
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Clinical endocrinology
- Publication Type :
- Academic Journal
- Accession number :
- 23452098
- Full Text :
- https://doi.org/10.1111/cen.12188